arXivDaily arXiv每日学术速递 周一至周五更新
arXiv周末暂无论文更新,休息一下吧,周末愉快~~
arXiv 2410.04561stat.MEstat.AP
收藏

一种用于存在死亡截断的观察性研究中不良反应估计的贝叶斯方法

A Bayesian Method for Adverse Effects Estimation in Observational Studies with Truncation by Death

Anthony Sisti, Andrew Zullo, Roee Gutman

AI总结:

针对观察性研究中死亡截断导致不良事件效应估计受限的问题,提出结合死亡与不良事件的复合有序结局贝叶斯插补方法,可在全样本中同时评估干预对两类结局的效应,并应用于老年糖尿病患者心衰发生率分析。

摘要:

在评估老年或重症患者干预措施因果效应的观察性研究中,受试者死亡是常见现象。高死亡率使得不同干预措施间不良事件(AE)发生率的比较变得复杂,该问题通常被称为结局的死亡“截断”。一种可行的解决方案是估计幸存者平均因果效应(SACE),这一估计量用于评估在两种治疗分配下都能存活的人群中的干预效应。但由于SACE未纳入在一种或两种治疗组下会死亡的受试者,因此未考虑不良事件与死亡之间的关联。我们提出一种贝叶斯方法,对每位受试者在未接受的干预措施下的未观测死亡率和不良事件结局进行插补。基于插补后的结局,我们为每位患者定义了一个复合有序结局,将死亡发生与不良事件按严重程度递增的尺度相结合,从而能够在全部样本中同时比较干预措施对死亡和不良事件的效应。我们实施了该流程,用于分析接受磺脲类药物或二肽基肽酶-4抑制剂治疗的老年II型糖尿病患者的心力衰竭发生率。

英文摘要:

Death among subjects is common in observational studies evaluating the causal effects of interventions among geriatric or severely ill patients. High mortality rates complicate the comparison of the prevalence of adverse events (AEs) between interventions. This problem is often referred to as outcome "truncation" by death. A possible solution is to estimate the survivor average causal effect (SACE), an estimand that evaluates the effects of interventions among those who would have survived under both treatment assignments. However, because the SACE does not include subjects who would have died under one or both arms, it does not consider the relationship between AEs and death. We propose a Bayesian method which imputes the unobserved mortality and AE outcomes for each participant under the intervention they did not receive. Using the imputed outcomes we define a composite ordinal outcome for each patient, combining the occurrence of death and the AE in an increasing scale of severity. This allows for the comparison of the effects of the interventions on death and the AE simultaneously among the entire sample. We implement the procedure to analyze the incidence of heart failure among geriatric patients being treated for Type II diabetes with sulfonylureas or dipeptidyl peptidase-4 inhibitors.

机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。

↑